When T cells and macrophages do not talk: the hemophagocytic syndromes
- 1 July 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Hematology
- Vol. 15 (4), 359-367
- https://doi.org/10.1097/moh.0b013e3282f97f88
Abstract
Hemophagocytic lymphohistiocytoses represent a rare but biologically and clinically important group of disorders. This review focuses on the clinical, pathophysiologic and genetic manifestations of these disorders along with critical aspects of timely and appropriate treatment. Detailed laboratory investigations have led to significant advances in our understanding of the molecular and pathophysiologic features of hemophagocytic lymphohistiocytoses. These studies have provided new diagnostic tools and potential new therapeutic targets for future development. Parallel to these laboratory studies have been enormous advances in the treatment and improved clinical outcomes of patients with both primary and secondary hemophagocytic lymphohistiocytoses. The eventual merging of the improved understanding of the molecular pathway with novel gene therapy approaches may prove to be the final frontier in the optimal curative treatment of these disorders. Several key molecular events have been defined which lead to a final common etiologic pathway of natural killer cell dysfunction leading to the hemophagocytic lymphohistiocytosis syndromes. In part through international clinical trials, effective curative therapies for about half of patients with severe forms of hemophagocytic lymphohistiocytosis have been developed. Although a significant advance, the fact that about 50% of patients are still not able to be cured with currently used approaches challenges physician-scientists to develop more innovative and effective diagnostic and therapeutic approaches.Keywords
This publication has 77 references indexed in Scilit:
- Novel spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis in ethnic omani patientsAmerican Journal of Hematology, 2007
- Defective cytotoxic lymphocyte degranulation in syntaxin-11–deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patientsBlood, 2007
- Familial and acquired hemophagocytic lymphohistiocytosisEuropean Journal of Pediatrics, 2006
- Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosisJournal of Medical Genetics, 2006
- Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhoodThe Journal of Pediatrics, 2006
- Hemophagocytic syndrome as one of main manifestations in untreated systemic lupus erythematosus: two case reports and literature reviewClinical Rheumatology, 2006
- Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignanciesJournal of Medical Genetics, 2005
- Munc13-4 Is Essential for Cytolytic Granules Fusion and Is Mutated in a Form of Familial Hemophagocytic Lymphohistiocytosis (FHL3)Cell, 2003
- Biology and treatment of familial hemophagocytic lymphohistiocytosis: Importance of perforin in lymphocyte‐mediated cytotoxicity and triggering of apoptosisMedical and Pediatric Oncology, 2002
- Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosisThe Journal of Pediatrics, 1997